That's actually a bit of a misconception worth clearing up! Wild-type ATTR amyloidosis (ATTRwt) generally has a *more favorable* outlook compared to other forms, not less. Here's why:
- It progresses slowly compared to other types
- It primarily affects the heart, which is more manageable with modern treatments
- Nearly Show Full Answer
That's actually a bit of a misconception worth clearing up! Wild-type ATTR amyloidosis (ATTRwt) generally has a *more favorable* outlook compared to other forms, not less. Here's why:
- It progresses slowly compared to other types
- It primarily affects the heart, which is more manageable with modern treatments
- Nearly 80% of people diagnosed at age 80 or older live more than 18 months
- One study found 85% of people survived to their one-year follow-up That said, the median survival after diagnosis is around 3.5 years, which can sound concerning. The reason it isn't longer is largely because ATTRwt tends to be diagnosed later in life, often in men over 60, meaning overall health and age naturally play a role in outcomes.
Factors that can affect the outlook include:
- Age at diagnosis
- Severity of heart involvement
- Certain heart-related biomarkers in the blood
- Ability to perform daily activities independently Starting Attruby (acoramidis) is a really positive step. It works by stabilizing the transthyretin protein, which helps slow amyloid buildup in the heart. Early treatment access, like you have, is one of the strongest factors in improving long-term outcomes. Staying closely connected with your care team to monitor heart function will be important going forward.
July 13
Join
Your Privacy Choices
